Recombinant Vaccines Market Size, Share, Growth Analysis, By End user(Pediatric and Adult), By Distribution channel(Hospitals and Vaccination centers), By Region - Industry Forecast 2024-2031

Q: What is the global market size of Recombinant Vaccines Market?

Global Recombinant Vaccines Market size was valued at USD 9.02 Billion in 2022 and is poised to grow from USD 10.05 Billion in 2023 to USD 23.83 Billion by 2031, at a CAGR of 11.40% during the forecast period (2024-2031).

Q: Who are the key vendors in the Global Recombinant Vaccines Market?

The competitive environment of the global Recombinant Vaccines market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'AstraZeneca Plc.', 'Dynavax Technologies Corporation', 'Emergent BioSolutions Inc.', 'GlaxoSmithKline Plc.', 'Johnson & Johnson, Merck & Co. Inc.', 'Novavax, Inc.', 'Pfizer Inc.', 'Sanofi S.A.', 'Serum Institute of India Pvt. Ltd.'.

Report ID: SQMIG35A2787 | Region: Global | Published Date: July, 1990
Pages: 219 | Tables: 59 | Figures: 64

Recombinant Vaccines Market Regional Insights

North America emerged as the dominant region in the recombinant vaccines market, a trend expected to continue throughout the forecast period. The region dominates due to a combination of factors, such as high prevalence of chronic diseases, a significantly higher number of players, and higher vaccination rates offered. stimulating a dynamic approach to vaccination strategies.

Asia-Pacific is poised to record the highest annual growth rate (CAGR) during the analyzed period, driven by several primary factors. The presence of densely populated countries such as India and China contributes significantly to diseases causing widespread infection in the region. Furthermore, rising product launches and other factors being adopted by market players influence the market growth in Asia-Pacific.

Recombinant Vaccines Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Recombinant Vaccines Market size was valued at USD 9.02 Billion in 2022 and is poised to grow from USD 10.05 Billion in 2023 to USD 23.83 Billion by 2031, at a CAGR of 11.40% during the forecast period (2024-2031).

The competitive environment of the Recombinant Vaccines market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'AstraZeneca Plc.', 'Dynavax Technologies Corporation', 'Emergent BioSolutions Inc.', 'GlaxoSmithKline Plc.', 'Johnson & Johnson, Merck & Co. Inc.', 'Novavax, Inc.', 'Pfizer Inc.', 'Sanofi S.A.', 'Serum Institute of India Pvt. Ltd.'

An instrumental driver of market growth is the extensive utilization of recombinant properties, which significantly enhances the efficacy and safety of vaccines administered to patients. The inherent advantages of recombinant technology enable the rapid and large-scale production of vaccines, mitigating the risk of shortages in supply. Moreover, these vaccines are devoid of infectious viral particles, minimizing the potential for infection and rendering them safe for individuals with compromised immune systems. The notable benefits associated with recombinant vaccines have spurred deliberate efforts among manufacturers to focus on the development of innovative products targeting viral diseases. This endeavor involves leveraging advanced DNA technology, genomics, and other cutting-edge biotechnology techniques, collectively contributing to the evolution of more effective and safer vaccines.

The increasing incidence of infectious diseases worldwide has led to an urgent demand for effective vaccines. This urgency is compounded by the high susceptibility of elderly and pediatric nurses to serious diseases, and rapid vaccination efforts are needed worldwide. International organizations such as UNICEF and PAHO have played a key role in the delivery of millions of doses to countries facing emergency needs that supported the vaccine stoppage . The efficient procurement of vaccine quantities by these organizations has greatly reduced the spread of many diseases and strengthened the population’s resistance to all these health threats.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Recombinant Vaccines Market Size, Share, Growth Analysis, By End user(Pediatric and Adult), By Distribution channel(Hospitals and Vaccination centers), By Region - Industry Forecast 2024-2031

Recombinant Vaccines Market Regional Insights

Recombinant Vaccines Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Recombinant Vaccines Market?

Who are the key vendors in the Recombinant Vaccines Market?

What is the key driver of Recombinant Vaccines Market?

What is the key market trend for Recombinant Vaccines Market?

Which region accounted for the largest share in Recombinant Vaccines Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300